December 2, 2013
Monday, December 9, 2013: 11:00 AM 12:30 PM EST
In 2012, the FDA approved Truvada for PrEP use among adult women and men who are "at risk" of HIV infection in the U.S. But exactly which women are at risk, how such risk is defined and understood, and whether or not women see themselves in this way is not entirely clear. Speakers in this webinar will present what is known from social and behavioral science and community experience about the definitions and perceptions of HIV risk among women that are relevant to their potential PrEP use. The webinar is co-sponsored by SisterLove, Inc., AVAC, HIV Prevention Justice Alliance, National Women's Health Network and the Well Project.
Judith Auerbach, PhD, Adjunct Professor, Center for AIDS Prevention Studies, University of California, San Francisco; and Consultant to AIDS United and San Francisco AIDS Foundation Introduction
Rivet Amico, PhD, Research Scientist, Center for Health Intervention and Prevention, University of Colorado
JoAnne Keatley, MSW, Director, Center of Excellence for Transgender Health, University of California, San Francisco
Vignetta Charles, PhD, Senior Vice President, AIDS United
When: Monday, December 9, 2013 at 8:00 AM - 9:30 AM PST / 9:00 AM - 10:30 AM MST / 10:00 AM - 11:30 AM CST / 11:00 AM 12:30 PM EST